InterMune Upgraded to “Outperform” at Leerink Swann (ITMN)
InterMune (NASDAQ:ITMN) was upgraded by equities research analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a research note issued to investors on Monday, TheFlyOnTheWall.com reports.
ITMN has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus raised their price target on shares of InterMune from $45.00 to $51.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of InterMune from $20.00 to $22.00 in a research note on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. InterMune presently has an average rating of “Buy” and an average price target of $37.67.
In other InterMune news, VP Sean Nolan sold 2,644 shares of InterMune stock in a transaction dated Thursday, May 8th. The shares were sold at an average price of $35.85, for a total transaction of $94,787.40. Following the transaction, the vice president now directly owns 72,556 shares in the company, valued at approximately $2,601,133. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of InterMune (NASDAQ:ITMN) opened at 34.31 on Monday. InterMune has a 52 week low of $9.27 and a 52 week high of $38.73. The stock has a 50-day moving average of $31.9 and a 200-day moving average of $21.81. The company’s market cap is $3.393 billion.
InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter last year, the company posted ($0.64) earnings per share. InterMune’s revenue was up 188.6% compared to the same quarter last year. Analysts expect that InterMune will post $-2.35 EPS for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.